文献速递免疫规划传染病防控与疫情报告

2018/19年度英国基层医疗机构成人与儿童流感疫苗结束季节效果评估

End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19.
PubMed 文献 · Vaccine · 2019-11-01

2018/19年度是英国首次为65岁及以上成人引入新型佐剂流感疫苗(aTIV)的季节,也是儿童四价减毒活流感疫苗(LAIV)接种规划实施的第六个季节,流行以A(H1N1)pdm09为主、后期A(H3N2)增多。采用检测阴性病例对照方法调整关键混杂因素后计算结束季节调整疫苗效果(aVE):对所有实验室确诊流感aVE为44.3%(95%CI:26.8,57.7),对A(H1N1)pdm09为45.7%(95%CI:26.0,60.1),对A(H3N2)为35.1%(95%CI:-3.7,59.3)。65岁及以上人群总体aVE为49.9%(95%CI:-13.7,77.9),接种aTIV者aVE为62.0%(95%CI:3.4,85.0);2-17岁接种LAIV儿童aVE为48.6%(95%CI:-4.4,74.7)。

要点

  • 2018/19年度所有实验室确诊流感aVE为44.3%(95%CI:26.8,57.7),对A(H1N1)pdm09为45.7%(95%CI:26.0,60.1)。
  • 对A(H3N2)的aVE为35.1%(95%CI:-3.7,59.3),较2017/18年度仍呈降低且未达统计学显著。
  • 65岁及以上接种aTIV者aVE为62.0%(95%CI:3.4,85.0),2-17岁接种LAIV儿童aVE为48.6%(95%CI:-4.4,74.7)。

核心结论

  • 2018/19年度流感疫苗总体效果显著,尤其对A(H1N1)pdm09;但对A(H3N2)效果降低且未达统计学显著,与2017/18年度所见一致。
  • aTIV为65岁及以上人群提供了显著保护。

研究设计与样本

  • 采用检测阴性病例对照方法,调整关键混杂因素后计算结束季节调整疫苗效果(aVE)。
  • 研究对象为英国基层医疗机构中就诊的成人和儿童,2018/19年度流行以A(H1N1)pdm09为主、后期A(H3N2)增多。

主要发现

  • 对所有实验室确诊流感aVE为44.3%(95%CI:26.8,57.7)。
  • 对A(H1N1)pdm09的aVE为45.7%(95%CI:26.0,60.1),对A(H3N2)的aVE为35.1%(95%CI:-3.7,59.3)。
  • 65岁及以上人群总体aVE为49.9%(95%CI:-13.7,77.9),接种aTIV者aVE为62.0%(95%CI:3.4,85.0)。
  • 2-17岁接种LAIV儿童aVE为48.6%(95%CI:-4.4,74.7)。

关键数值与推荐

  • 2018/19年度为65岁及以上成人首次引入新型佐剂流感疫苗(aTIV)的季节,也是儿童四价减毒活流感疫苗(LAIV)接种规划实施的第六个季节。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

2018/19 was the first season of introduction of a newly licensed adjuvanted influenza vaccine (aTIV) for adults aged 65 years and over and the sixth season in the roll-out of a childhood influenza vaccination programme with a quadrivalent live attenuated influenza vaccine (LAIV). The season saw mainly A(H1N1)pdm09 and latterly A(H3N2) circulation. End-of-season adjusted vaccine effectiveness (aVE) estimates against laboratory confirmed influenza infection in primary care were calculated using the test negative case control method adjusting for key confounders. End-of-season aVE was 44.3% (95% CI: 26.8, 57.7) against all laboratory-confirmed influenza; 45.7% (95% CI: 26.0, 60.1) against influenza A(H1N1)pdm09 and 35.1% (95% CI: -3.7,59.3) against A(H3N2). Overall aVE was 49.9% (95%CI: -13.7, 77.9) for all those ≥ 65 years of age and 62.0% (95% CI: 3.4, 85.0) for those who received aTIV. Overall aVE for 2-17 year olds receiving LAIV was 48.6% (95% CI: -4.4, 74.7). The paper provides evidence of overall significant influenza VE in 2018/19, most notably against influenza A(H1N1)pdm09, however, as seen in 2017/18, there was reduced, non-significant VE against A(H3N2). aTIV provided significant protection for those 65 years of age and over.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pebody RG, Whitaker H, Ellis J, et al. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. Vaccine. 2019. PMID: 31685296. doi:10.1016/j.vaccine.2019.10.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。